Pfizer (PFE) Ruling on Teva's (TEVA) Generic Celebrex Stands, Court Says -Bloomberg
More News related to PFE
- Beacon Equity Issues Technical Trading Overview for NexMed Inc.
- Protalix BioTherapeutics (PLX) Sees Interest On Renewed Takeover Talk
- BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
- Standpoint Raised Its FY10 Price Target on Pfizer (PFE) to $24
- Pfizer Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults
More News related to TEVA
- Protalix BioTherapeutics (PLX) Sees Interest On Renewed Takeover Talk
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
More News related to Corporate News
- Hoku Scientific (HOKU) Amends Poly Deal with Jinko Solar
- American International Group (AIG), Greenberg and Smith Settle Disputes
- Heska (HSKA) Announces Agreements with Roche for Blood Gas Product Supply/Affiliated Consumables
- AIG, Greenberg and Smith to settle all disputes
- DryShips (DRYS) Announces Exercise of Over-Allotment Option by Underwriters, Closes Convertible Senior Notes Offering for Net Proceeds of $448M
Bloomberg is reporting that an appeals court said that Pfizer's (NYSE: PFE) ruling on Teva Pharmaceuticals' (Nasdaq: TEVA) generic Celebrex stands.
Related Categories
Corporate NewsStocks Mentioned
+0.28
-0.11Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
